SecurityMBVX / MabVax Therapeutics Holdings, Inc. (55414P108)
IndustryPharmaceutical Preparations
Institutional Owners0
Common Shares Outstanding8,961,840 shares (as of 2017-12-31)

Institutional Stock Ownership and Shareholders

MBVX / MabVax Therapeutics Holdings, Inc. Institutional Ownership

MabVax Therapeutics Holdings, Inc. (OTC:MBVX) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
MabVax Therapeutics Holdings, Inc. (OTC:MBVX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

18h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

18h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

20h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen

2018-07-08 seekingalpha
News of final analysis of a Phase 2 clinical trial of BAN2401, an Alzheimer’s drug developed by Biogen (BIIB) with Japanese partner Eisai pushed the stock initially by 6.4%. However, it is now close to 20% up. The companies claimed that the trial achieved statistical significance on predefined endpoints. The study evaluated the drug’s efficacy on slowing further progression in early Alzheimer’s disease. (11-0)

Your Daily Pharma Scoop: Sesen Bio Presents Vicinium Data, UroGen's Mitogel Data, FibroGen In IPF

2018-05-22 seekingalpha
Sesen Bio (NASDAQ:SESN) is a nanocap that has managed to get a drug through a phase 3 study. Not only that, but it has managed to come up with positive data for its lead antibody-drug conjugate (NYSE:ADC) Vicinium in patients with high-grade non-muscle invasive bladder cancer (NMIBC). (134-4)

CUSIP: 55414P108